PT-141 (Bremelanotide) is a peptide used to treat sexual dysfunction. FDA-approved as Vyleesi, it treats hypoactive sexual desire disorder (HSDD) in women and is also studied for erectile dysfunction (ED). Unlike Viagra, it works by stimulating the melanocortin system in the brain to enhance arousal. Administered via injection, effects start within 30-60 minutes and last 6-12 hours. ** Side effects MAY include temporary nausea, flushing, headaches, and increased blood pressure which usually pass in 15-20 minutes.

Benefits (Research Focus)

• Melanocortin receptor agonism — studied as a non-selective MC1R/MC3R/MC4R/MC5R agonist for receptor pharmacology research

• MC4R signaling research — investigated for central nervous system MC4R pathway pharmacology

• Cyclic peptide stability — explored for the role of the Asp²-Lys⁷ lactam bridge in metabolic stability and receptor binding

• Hypothalamic neuroendocrinology — examined for melanocortin signaling in hypothalamic neuron populations

• SAR comparator — researched as a reference compound versus other melanocortin analogs (e.g., melanotan II, MT-II, SHU 9119)

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment